The Management Team
We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.
Be part of the Transformation in veterinary medicine
We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?
Treatment options for our companion animals shouldn’t be limited
Download the Corporate Presentation to learn more about our strategy, team, and programs.
Read the Recent News from KindredBio.
Looking for More?
See Our Pipeline
KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.
Elanco Announces Agreement to Acquire Kindred Biosciences
/in Frontpage, Investor, News /by Katja BuhrerBolt-on Acquisition Accelerates Elanco’s Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential […]
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus
/in Frontpage, Investor, News /by Katja BuhrerStudy demonstrated 100% survival in dogs treated with KIND-030, even in the absence of any supportive care, versus 43% survival in dogs treated with placebo San Francisco, California (June 2, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a […]
Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, May 25, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro Invitational XI on June 8. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one […]